4 Promising Developments Reported in Glaucoma Treatment Study

Park 06-06-16 ID-100313391 Tuomas_LehtinenGlaucoma patients in the Triangle may one day be able to quit using daily eye drops. This eye disease, caused by elevated pressure inside the eyes (intraocular pressure), typically is treated by daily eye drops or by surgery. Dr. Beth R. Friedland  closely follows glaucoma research and often consults on new drug clinical trials. A report published in May 2016, shows that a medicated ring placed on patients’ eyes can effectively reduce eye pressure for up to six months. Park Ophthalmology shares some of the key points about this research from this important article.

Here are four facts highlighted in a recent article on a new delivery system for glaucoma medication:

  • Daily treatment:Researchers and Ophthalmologists are concerned that some patients, especially the elderly, have trouble administering the daily eye drops used to lower intraocular pressures. If patients don’t use the drops daily, they can run the risk of vision damage. The research investigated whether a medicated silicone ring worn on the eye was as effective as daily eye drops. These rings eventually could replace the need for daily eye drops. An article about the research was published in Ophthalmology, the journal of the American Academy of Ophthalmology.
  • Six-month duration: The eye insert lasts for six months and is placed and removed by an ophthalmologist. This means patients can be assured that they will receive the right dosage daily without actually administering the drug themselves. This is important to note because many older patients with arthritis or memory issues are often at risk for missing the daily dose of eye drops.
  • Lower eye pressures: Researchers found that after six months, patients with the silicone ring had lower eye pressures than those who used daily drops. The pressures were lower by about 20 percent from the beginning measurements for those patients using the silicone insert.
  • Phase 3 testing: Later this year, researchers plan to widen their testing to a larger number of participants. They also are hopeful that the silicone insert could eventually be used for treatment of other eye conditions, including allergies, inflammation and dry eye.

Even though glaucoma can be a frightening diagnosis, researchers are working to find better treatments for this condition. Beth R. Friedland M.D. stays current with new treatment options and her patients are encouraged to share their concerns with her. If there is a family history of glaucoma and one of our patients has yet to be evaluated for risk, contact Park Ophthalmology tomorrow to schedule an appointment for a complete eye exam.


Park Ophthalmology welcomes patients from all areas of the Triangle and offers a wide variety of specialized services including surgery for diseases of the eye, vision examinations, eye safety information, sports medicine protective eyewear and counseling, contact lenses and evaluation, and all types of ocular diagnosis and treatment. Many types of surgery are available, including cataract and laser surgery. We are here for you and your eye and overall health. Give us a call today!

This article about the vision care is brought to you by the professional team at Park Ophthalmology located in the Triangle Region of North Carolina.


The information contained in this blog article is intended solely for informational purposes and is not intended to be offered as medical advice.


Park Ophthalmology

5306 NC Highway 55, Suite 102 (adjacent to the RTP/ Research Triangle Park)

Durham, NC 27713

Office: 919 544 5375

Fax: 919 544 5829


Park Ophthalmology North

6512 Six Forks Road, Suite 105

Raleigh, NC 27615

919 846 6915

Office Manager Jenny Whitman, e-mail: parkeyemd@gmail.com.

Follow us https://twitter.com/ParkOphthNC

Like us: https://www.facebook.com/ParkOphthalmology

Photo: Tuomas_Lehtinen/Freedigitalphotos.net/


This entry was posted in The Triangle's Eye Specialist and tagged , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.